JP6092113B2 - セロトニン受容体アゴニストおよびジケトピペラジンを含む偏頭痛治療のための組成物 - Google Patents

セロトニン受容体アゴニストおよびジケトピペラジンを含む偏頭痛治療のための組成物 Download PDF

Info

Publication number
JP6092113B2
JP6092113B2 JP2013538866A JP2013538866A JP6092113B2 JP 6092113 B2 JP6092113 B2 JP 6092113B2 JP 2013538866 A JP2013538866 A JP 2013538866A JP 2013538866 A JP2013538866 A JP 2013538866A JP 6092113 B2 JP6092113 B2 JP 6092113B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
diketopiperazine
sumatriptan
composition according
dry powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013538866A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013545748A (ja
JP2013545748A5 (enExample
Inventor
レオーネ−ベイ、アンドレア
ダブリュ ストーウェル、グレイソン
ダブリュ ストーウェル、グレイソン
ジェイ ガーネリ、ジョセフ
ジェイ ガーネリ、ジョセフ
エム カールソン、ドーン
エム カールソン、ドーン
グラント、マーシャル
シー スマットニー、チャド
シー スマットニー、チャド
Original Assignee
マンカインド コーポレイション
マンカインド コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マンカインド コーポレイション, マンカインド コーポレイション filed Critical マンカインド コーポレイション
Publication of JP2013545748A publication Critical patent/JP2013545748A/ja
Publication of JP2013545748A5 publication Critical patent/JP2013545748A5/ja
Application granted granted Critical
Publication of JP6092113B2 publication Critical patent/JP6092113B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2013538866A 2010-11-09 2011-11-09 セロトニン受容体アゴニストおよびジケトピペラジンを含む偏頭痛治療のための組成物 Active JP6092113B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41177510P 2010-11-09 2010-11-09
US61/411,775 2010-11-09
US41233910P 2010-11-10 2010-11-10
US61/412,339 2010-11-10
PCT/US2011/060057 WO2012064892A1 (en) 2010-11-09 2011-11-09 Composition comprising a serotonin receptor agonist and a diketopiperazine for treating migraines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017021017A Division JP6458064B2 (ja) 2010-11-09 2017-02-08 ジケトピペラジンを含む治療のための組成物

Publications (3)

Publication Number Publication Date
JP2013545748A JP2013545748A (ja) 2013-12-26
JP2013545748A5 JP2013545748A5 (enExample) 2016-04-07
JP6092113B2 true JP6092113B2 (ja) 2017-03-08

Family

ID=45048258

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013538866A Active JP6092113B2 (ja) 2010-11-09 2011-11-09 セロトニン受容体アゴニストおよびジケトピペラジンを含む偏頭痛治療のための組成物
JP2017021017A Active JP6458064B2 (ja) 2010-11-09 2017-02-08 ジケトピペラジンを含む治療のための組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017021017A Active JP6458064B2 (ja) 2010-11-09 2017-02-08 ジケトピペラジンを含む治療のための組成物

Country Status (10)

Country Link
EP (2) EP3536368B1 (enExample)
JP (2) JP6092113B2 (enExample)
KR (1) KR101931392B1 (enExample)
CN (2) CN107854454A (enExample)
AU (1) AU2011326529B2 (enExample)
BR (1) BR112013011549B1 (enExample)
CA (1) CA2817337C (enExample)
ES (1) ES2732818T3 (enExample)
MX (2) MX376862B (enExample)
WO (1) WO2012064892A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
JP4681231B2 (ja) 2002-03-20 2011-05-11 マンカインド コーポレイション 吸入装置
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
CN104383546B (zh) 2006-02-22 2021-03-02 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
MY155524A (en) 2008-06-13 2015-10-30 Mannkind Corp A dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
EP2609954B1 (en) 2008-06-20 2021-12-29 MannKind Corporation An interactive apparatus for real-time profiling of inhalation efforts
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US8538707B2 (en) 2009-03-11 2013-09-17 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
AU2010259943C1 (en) 2009-06-12 2016-03-03 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
RU2531455C2 (ru) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
MX353285B (es) 2011-04-01 2018-01-05 Mannkind Corp Paquete de blister para cartuchos farmaceuticos.
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
HK1201475A1 (en) 2011-10-24 2015-09-04 Mannkind Corporation Methods and compositions for treating pain
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
BR112015023168B1 (pt) 2013-03-15 2021-08-10 Mannkind Corporation Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
CA2920488C (en) 2013-08-05 2022-04-26 Mannkind Corporation Insufflation apparatus and methods
CN103599155B (zh) * 2013-11-27 2015-12-02 广州安健实业发展有限公司 治疗偏头痛的方法
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
EP3288591A1 (en) * 2015-05-01 2018-03-07 Civitas Therapeutics, Inc. Zolmitriptan powders for pulmonary delivery
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
EP3316865A4 (en) 2015-07-02 2019-01-23 Civitas Therapeutics, Inc. TRIPTAN POWDER FOR PULMONARY ADMINISTRATION
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
GB201709459D0 (en) * 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
US11135379B2 (en) 2019-02-15 2021-10-05 Bn Intellectual Properties, Inc. Method of delivering pharmaceutical products
MD3989962T2 (ro) 2019-06-28 2025-12-31 Intrabio Ltd Gb Terapie combinată cu acetil-leucină și miglustat pentru tratamentul unei boli de depozitare lizozomală
US11364225B2 (en) * 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same
WO2021144720A1 (en) 2020-01-13 2021-07-22 Intrabio Ltd Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
GB9827145D0 (en) * 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
US7464706B2 (en) 1999-07-23 2008-12-16 Mannkind Corporation Unit dose cartridge and dry powder inhaler
US7305986B1 (en) 1999-07-23 2007-12-11 Mannkind Corporation Unit dose capsules for use in a dry powder inhaler
CN1176649C (zh) * 2002-10-16 2004-11-24 上海医药工业研究院 舒马普坦干粉吸入剂及其制备方法
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
CN104383546B (zh) * 2006-02-22 2021-03-02 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
KR20100090692A (ko) * 2007-10-24 2010-08-16 맨카인드 코포레이션 활성제의 전달
KR101736502B1 (ko) * 2007-10-24 2017-05-16 맨카인드 코포레이션 Ｇｌｐ-1에 의한 유해 효과의 예방 방법
US20110077272A1 (en) * 2008-02-01 2011-03-31 Vectura Limited Pulmonary formulations of triptans
MY155524A (en) 2008-06-13 2015-10-30 Mannkind Corp A dry powder inhaler and system for drug delivery

Also Published As

Publication number Publication date
AU2011326529B2 (en) 2015-07-30
EP3536368B1 (en) 2025-09-17
EP2637657A1 (en) 2013-09-18
BR112013011549A2 (pt) 2017-07-25
JP2013545748A (ja) 2013-12-26
AU2011326529A1 (en) 2013-05-02
MX376862B (es) 2025-03-07
CA2817337C (en) 2020-04-14
KR20140008314A (ko) 2014-01-21
CA2817337A1 (en) 2012-05-18
EP3536368A1 (en) 2019-09-11
BR112013011549B1 (pt) 2022-01-04
CN107854454A (zh) 2018-03-30
JP2017110026A (ja) 2017-06-22
CN103200940A (zh) 2013-07-10
EP2637657B1 (en) 2019-05-22
JP6458064B2 (ja) 2019-01-23
WO2012064892A1 (en) 2012-05-18
KR101931392B1 (ko) 2018-12-20
ES2732818T3 (es) 2019-11-26
MX2013005294A (es) 2013-12-06
MX340112B (es) 2016-06-27

Similar Documents

Publication Publication Date Title
JP6458064B2 (ja) ジケトピペラジンを含む治療のための組成物
US20200405731A1 (en) Method and composition for administering prostaglandins
JP6491658B2 (ja) 熱安定性乾燥粉末医薬組成物及び方法
US8642548B2 (en) Val (8) GLP-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
JP6165300B2 (ja) 合成ペプチド及び乾燥粉末薬剤輸送システム
US10130581B2 (en) Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
JP2016006082A (ja) 非対称置換ジケトピペラジン及び微粒子組成物
JP2006249099A (ja) 持続放出特性を有する吸入用粒子
Tandon et al. Insulin therapy for diabetes epidemic: a patent review
US20240390274A1 (en) Method and composition for treating obesity
AU2017248512B2 (en) Method and composition for treating migraines
HK40014359B (en) Dry powder inhaler comprising a serotonin receptor agonist and a diketopiperazine for treating migraines
HK40014359A (en) Dry powder inhaler comprising a serotonin receptor agonist and a diketopiperazine for treating migraines
HK1189503A (en) Composition comprising a serotonin receptor agonist and a diketopiperazine for treating migraines
HK1189503B (en) Composition comprising a serotonin receptor agonist and a diketopiperazine for treating migraines
AU2012203627B2 (en) Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150818

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160118

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20160215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170208

R150 Certificate of patent or registration of utility model

Ref document number: 6092113

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250